An Australian stem cell and regenerative medicine company

December 13, 2018

H.C. Wainwright & Co. Research Update: Research Funding Awarded; Tax Credits Received; Reiterate Buy

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating

September 17, 2018

H.C. Wainwright & Co. Research Update: “Recent Developments Underscore Clinical Progress; FUJIFILM May Exercise Option Soon; Raising Target to A$2”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and raising his price target to $2.00

June 25, 2018

Shaw and Partners Research Update: “Highly Encouraging Safety and Efficacy Data Further De-risks Cynata“

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

June 25, 2018

NDF’s Stuart Roberts Updates Cynata Research Coverage

View Report

View the latest update from NDF on Cynata Therapeutics

April 05, 2018

FDA Grants CYP-001 Orphan Drug Designation; Reiterate Buy

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation.